IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway
Open Access
- 30 May 2018
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 609
Abstract
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide. The disease recurrent rate is relatively high resulted in poor 5-year survival in advanced HCC. Cancer stem cells (CSCs) have been considered to be one of the main mechanisms for chemoresistance, metastasis, and recurrent disease. Interferon-induced protein 44-like (IFI44L) gene is a type I interferon-stimulated gene (ISG) and belongs to the IFI44 family. Previous reports indicated antiviral activity against HCV in IFI44L, however, its precise role and function in HCC has not been unveiled. To explore the characteristics of hepatic CSCs, we successfully enriched hepatic cancer stem-like cells from three established liver cancer cell lines (Hep3B, HepG2, and PLC lines). Parental Hep3B and HepG2 cells and their sphere cells were treated with doxorubicin for 48 h and cell viability was measured by MTT assay. HCC tissue blocks from 217 patients were sampled for tissue microarray (TMA). Follow-up information and histopathological and clinical data including age, gender, tumor grade, advanced stages, HBV, HCV, tumor number, tumor size, relapse-free survival, and overall survival were obtained from the cancer registry and medical charts. The liver TMA was evaluated for IFI44L expression using immunohistochemical staining and scores. These hepatic cancer stem-like cells possess important cancer stemness characteristics including sphere-forming abilities, expressing important HCC cancer stem cell markers, and more chemoresistant. Interestingly, we found that overexpression of IFI44L decreased chemoresistance towards doxorubicin and knockdown of IFI44L restored chemoresistance as well as promoted sphere formation. Furthermore, we found that depletion of IFI44L enhanced migration, invasion, and pulmonary metastasis through activating Met/Src signaling pathway. Clinically, the expression level of IFI44L significantly reduced in HCC tumor tissues. Low expression of IFI44L levels also correlated with larger tumor size, disease relapse, advanced stages, and poor clinical survival in HCC patients. Taken together, we first demonstrated that IFI44L is a novel tumor suppressor to affect cancer stemness, metastasis, and drug resistance via regulating Met/Src signaling pathway in HCC and can be serve as an important prognostic marker.Keywords
Funding Information
- Ministry of Science and Technology, Taiwan (103-2314-B-442-002-MY3, 106-2314-B-442-001-MY3)
This publication has 46 references indexed in Scilit:
- Targeting the HGF-cMET Axis in Hepatocellular CarcinomaInternational Journal of Hepatology, 2013
- Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell linesBMC Gastroenterology, 2011
- A diverse range of gene products are effectors of the type I interferon antiviral responseNature, 2011
- Application of Weibull model for survival of patients with gastric cancerBMC Gastroenterology, 2011
- Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinomaExperimental and Molecular Pathology, 2010
- miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasisNature Cell Biology, 2010
- Amphiregulin mediates self-renewal in an immortal mammary epithelial cell line with stem cell characteristicsExperimental Cell Research, 2010
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Cancer Stem Cells—Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem CellsCancer Research, 2006
- Tumour stem cells and drug resistanceNature Reviews Cancer, 2005